On May 12th, the biaseparations.com website will be retired and migrated tosartorius.com.Learn moreabout our combined offering today!

Seminars & Webinars

2024

Full view

Event: LabRoots Webinar
Date: January 24, 2024
Presenter: Marko Narobe, Sartorius BIA Separations

The downstream processing of virus particles, vesicles, RNAs, plasmids and other forms of DNA, contains multiple interdependent steps, each requiring optimization for best results.  This webinar will showcase how to shorten the development time by screening multiple conditions at once, with small sample intake and process automatization. In these processes we used our newly launched CIM® monolithic plates.

The CIM® monolithic plates are a standard plate design, manufactured according to ANSI standard. In each well there is a defined amount of monolithic chromatographic media. Due to its intrinsic properties the mass flow through the monolith is convective. This enables us to have fast processes, and no shaking or incubation is required with our plates.  

First, we present the screening of different mobile phases for rAAV capture step. Optimization of capture step leads to increased process productivity and product purity, as well as improves the polishing step. High vector recovery and greater reduction of impurities translate to preparative scale.

Subsequent part of the webiar focuses on the importance of finding conditions that increase dynamic binding capacity (DBC) of mRNA on Oligo dT. Screening experiments help to to identify the factors that affect the binding capacity and achieve a DBC of >6 mg/mL.

In both cases, the optimized conditions were scaled-up to preparative scale chromatography, resulting in successful implementation of screening tools for process development optimization. Watch the webinar to learn how CIM® (Convective Interaction Media) monolithic chromatography products solve challenges in DSP for gene therapy and vaccines.

Full view

2023

Event: Life Science Connect
Date: December 13, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

Abstract:

The goal of AAV downstream process (DSP) is to achieve high recovery of >90% full AAV capsid. For the first column step, either affinity or cation exchange chromatography is used. For the polishing anion exchange, chromatography or ultracentrifuge is employed.

This webinar will compare the cation exchange and affinity column. Our presentation will also detail how the new CIMmultus HR (High Reproducibility) line columns, which include better resolution and narrower acceptance criteria, are used for the polishing step.


Key Learning Objectives: 

  • 10% improved process recovery using the strong cation exchange instead of affinity column 
  • Up to 2 fold shorter processing time using SO3 instead of affinity column 
  • Less damaged capsids using SO3 instead of affinity column
  • >5times better resolution of the empty/full capsids by applying new methods with the QA anion exchange columns.
  • The QA HR columns allow for batch-to-batch and scale-to-scale reproducibility within +/- 3%; about 10 times better when compared with the traditional CIMmultus line

For more information about our new CIMmultus QA HR line, please check the following link.

Full view

Event: Biospectrum Asia
Date: December 12, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

The main goal of AAV downstream process (DSP) is to achieve high recovery of >90% full AAV capsid. For the 1st column step either affinity or cation exchange chromatography is used. For the polishing anion exchange chromatography or ultracentrifuge is employed.

In this webinar comparison of the cation exchange and affinity column will be presented.

To address the recent needs the new CIMmultus HR line (HR stands for High Reproducibility) columns with better resolution and narrower acceptance criteria used for the polishing step will be shown.

Attend this webinar to learn how to achieve:

  • 10% improved process recovery using the strong cation exchange instead of affinity column
  • up to 2 fold shorter processing time using SO3 instead of affinity column
  • less damaged capsids using SO3 instead of affinity column
  • >5 times better resolution of the empty/full capsids by applying new methods with the QA anion exchange columns.

The QA HR columns allow for batch-to-batch and scale-to-scale reproducibility within +/- 3%; about 10 times better when compared with the traditional CIMmultus line.

For more information about our new CIMmultus QA HR line, please check the following link.

Full view

Event: GEN
Date: November 16, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

Adeno-associated virus (AAV) capsids are an effective mechanism for delivering gene therapies intended for therapeutic use. A critical production step is the separation of full capsids from empty ones, which are considered a product-related impurity in downstream processing. Partial and heavy AAV capsids in gene therapy products are problematic due to the potential carry-over of host cell DNA and plasmid DNA fragments. In large-scale vector manufacturing, separating full and empty AAV capsids requires high-resolution chromatography media and scale-to-scale reproducibility. To qualify chromatographic columns for separating capsids, it is important to use column release criteria that are based on the AAV elution profile. 

In this GEN webinar, Dr. Aleš Štrancar will discuss various chromatographic methods to consistently separate empty, partial, and full capsids in large-scale AAV manufacturing. He will introduce the CIMmultus High Reproducibility columns by Sartorius BIA Separations, which have better resolution and use narrow acceptance criteria to ensure consistent results. These columns allow for step gradient elution using the same buffer strength at any scale. Two order of magnitude removal of empty capsid should be possible at any scale.

Full view

Event: Cell and Gene Therapy Insights Webinar
Date: November 8, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

Separation of empty and full AAV capsids with very similar chromatographic characteristics requires very high-resolution chromatography media and scale-to scale reproducibility within just few percent. Qualification of chromatographic columns using small molecules might be misleading when separation of big molecules or virus particles is in question. Column release criteria based on the AAV elution profile must therefore be adopted and used for all column sizes. Recently, the presence of partial and heavy AAV capsids in gene therapy products has raised concerns due to potential carryover of host cell DNA and plasmid DNA fragments. Their removal from the product is therefore crucial. To address these needs, Sartorius BIA Separations developed columns with better resolution and narrower acceptance criteria. These columns allow for batch-to-batch and scale-to-scale reproducibility within just 3% of the AAV8 empty capsid isoconductivity elution, and step-gradient elution using the same buffer strength at any scale. Two orders of magnitude removal of empty capsid should be possible at any scale.

Learn how to achieve:

  • Five times better resolution of empty/full capsids
  • Large scale removal of empty, partial and heavy AAV capsids
  • Batch-to-batch and scale-to-scale reproducibility within +/- 3%

To address the recent needs Sartorius BIA Separations developed new CIMmultus HR line (HR stands for High Reproducibility) columns with better resolution and narrower acceptance criteria. These columns allow for step gradient elution using the same buffer strength at any scale. Two order of magnitude removal of empty capsid should be possible at any scale.

Full view

Event: Cell and Gene Therapy Insights Webinar
Date: October 12, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

Separation of empty and full AAV capsids with almost same chromatographic characteristic request very high-resolution chromatography media and scale-to scale reproducibility within just few percent. Qualification of chromatographic columns using small molecules might be misleading when separation of big molecules or virus particles is in question. Column release criteria based on the AAV elution profile therefore needs to be adopted and used for all column sizes. Recently the presence of partial and heavy AAV capsids in gene therapy products gathered more attention due to potential carry-over of the hcDNA and plasmid DNA fragments. Their removal from the product is therefore becoming crucial. To address the recent needs Sartorius BIA Separations developed new CIMmultus HR line (HR stands for High Reproducibility) columns with better resolution and narrower acceptance criteria. These columns allow for batch-to-batch and scale-to-scale reproducibility within just 3% of the AAV8 empty capsid isoconductivity elution. Such columns allow for step gradient elution using the same buffer strength at any scale. Two order of magnitude removal of empty capsid should be possible at any scale.

Full view

Event: mRNA Process Development & Manufacturing Summit USA
Date: September 27, 2023
Presenter: Aleš Štrancar, Sartorius BIA Separations

Attachments

Full view

Event: Cell and Gene Therapy Insights Webinar
Date: July 26, 2023
Presenter: Andreja Gramc Livk, Sartorius BIA Separations

Adeno-associated viruses (AAVs) are widely used vectors for gene therapies mainly due to their favorable safety profile and high transduction efficiency to various target tissues. With increasing demand for faster process development of advanced therapies using AAVs, rapid at-line analytical chromatographic solutions are becoming indispensable. 
PATfix analytical system with multiple detectors seamlessly delivers coherent process information, considerably speeding up process development and enabling a fast-paced delivery of the product to the market. 
Analytical methods, embedded in the PATfix system that enables at-line monitoring of common product and process related impurities, provide a critical platform for the rapid development and characterization of AAV-based gene therapy vectors.


 

Full view

Event: Cell and Gene Therapy Insights webinar
Date: April 5, 2023
Presenter: Rok Žigon, Head of Product-Application Area (AAV/Adeno), Process Development Viruses

Adeno-associated virus (AAV) is go-to vector for gene therapy treatments. In each AAV downstream process, one of the key and often a bottleneck step is enrichment of full capsids.  Along with scalability and capsid’s separation challenges one must account for sample heterogeneity and asses which analytics are adequate to distinguish between AAV sub-populations to deliver only the potent AAV product.
Chromatography on monolith columns offers efficient and scalable downstream processes.  Case study using Design-of-experiment approach of buffer selection and robust preparation for improved separation of empty and full capsids will be presented along with paramount considerations for scaling up. In addition, residual host cell proteins, host cell DNA, plasmid DNA, and endotoxin removal efficiency will be discussed.

Full view

2022

Speaker: Katja Vrabec, Project Manager

The development of fast and efficient processes for the isolation of extracellular vesicles (EVs) depends on the availability of chromatography media that meet the special fractionation needs of these products and analytical methods for process monitoring. Convective Interaction Media (CIM®) monolithic columns offer high binding capacities and low shear stress conditions for the purification of large biologics such as EVs. Multiple-detector PATfix™ technology was developed for monitoring sample composition and product detection in upstream and downstream processes. We will present the EV isolation process from clarified conditioned media and fractionation using CIMmultus™ chromatography columns. Testing of the raw materials, analysis of upstream samples produced in different cell lines, and analysis of downstream samples were performed using PATfix™ analytical approaches. The composition of EV populations was monitored through the detection of tetraspanins using immunofluorescent labelling and SEC analytics. High-throughput analysis of in-process samples and impurity composition was monitored using CIMac™ anion exchange columns.

Full view

Speaker: Mojca Tajnik Sbaizero, Project Manager 

rAAV downstream process using monoliths contains a series of steps that are mutually dependent. Therefore each step should be optimized for sufficient outcome. Standard 96-well design offers a great advantage for screening many samples and conditions. It supports small sample intake and process automatization. We will present example of multi-parallel screening of different mobile phases for rAAVcapture step using CIM SO3 0.05 mL Monolithic 96-well Plates. Optimization of capture step leads to increased process productivity and product purity, as well as improves later polishing step. High vector recovery and greater reduction of impurities were confirmed on preparative scale chromatography resulting in successful implementation of screening tools for process development optimization.

Full view

Event: LCGC Live Webcast

Date: March 17, 2022

Presenters:  

Rok Zigon, Project Manager; Process Development Dept.

Blaz Goricar, Project Manager; Process Analytical Technology Dept.

Key learning points:

  • Rapid downstream process of AAV using monoliths, with emphasis on PATfix analytical tools
  • Orthogonal analytics are paramount for AAV characterization
  • Integration using PATfix enables fast evaluation of empty-full ratio

Full view

Event: Cell and Gene Therapy Insights webinar

Date: February 17, 2022

Presenter: Ales Strancar, Managing Director

Key learning points:

  • One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids.
  • When the expression in the cell line results in less than 10% full capsid it is quite impossible to reach better than 90% full in the final product. It is therefore mandatory to optimise the USP to result in better empty/full ratio.  
  • This can be efficiently realised by using at-line PATfix to allow for analysis of the full and empty capsids ratio directly in the harvest.
  • The residual empty capsids can be removed by polishing step using different anion exchange columns.

Full view

2021

Published: Cell & Gene Therapy Insights 2021; 7(12), 1661

Date: December 20, 2021

Presenter: Maja Leskovec, Head of Process Development Viruses (viral vectors and vaccines)

Watch the video or read the poster to learn:

  • Importance of sample pretreatment before first chromatographic step
  • Rapid downstream process of AAV with emphasis on chromatographic step of CIMmultus SO3 capture
  • Three different ligands full enrichment of AAV
  • Why orthogonal analytics is the key in downstream development and what are the options

Attachments

Full view

Presenter: Ivana Petrović Koshmak, PhD

Event: Late Stage Bioprocessing & Viral Vectors 2 11 November 2021

Date: November 3, 2021

Abstract:

Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.

One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids. The most efficient way is to design the USP to result in less than 10% of empty capsids. This can be realised by process optimisation using at-line PATfix analytics to allow for analysis of the full and empty capsids ratio during the virus expression.

Fast and reliable at-line analytical methods to allow for process optimisation USP and DSP, and assessing the purity of the final product using PATfix system will be presented.

Attachments

Full view

Published: Cell & Gene Therapy Insights 2021; 7(8), 1125

Date: October 4, 2021

Presenter: Hana Jug, Project Manager in process development for viral vectors and vaccines

Watch the video or read the poster to learn: 

  • Why downstream processing remains one of the main bottlenecks in adenoviral vector manufacturing 
  • How an adenoviral vector purification platform using CIMmultus™ QA as the key purification step, secures a fast and robust process with better purity 
  • CIMmultus™ QA offers high capacity and high yields of adenovirus, results in cost reduction and overcomes raw material supply bottlenecks 

Attachments

Full view

Presenter: Aleš Štrancar

Event: BPI and Cell & Gene Therapy Bioprocessing & Commercialization 2021

Date: September 28, 2021

Abstract:

Adeno associated virus (AAV) is the leading vector in the field of gene therapy because of its low toxicity, good overall safety profile, and ability to maintain stable expression for long periods of time. It is therefore crucial to develop a robust and high efficiency platform for its manufacturing.

One of the key challenges in manufacturing viral vectors is to increase the ratio between empty and full capsids. The most efficient way is to design the USP to result in less than 10% of empty capsids. This can be realised by process optimisation using at-line biochromatography analytics to allow for analysis of the full and empty capsids ratio directly in the harvest.

The residual empty capsids can be further removed by polishing purification step using different anion exchange columns.

Fast and reliable at-line analytical methods to allow for process optimisation and assessing the purity of the final product using PATfix system will be presented.

Attachments

Full view

Presenter: Ivana Petrović Koshmak

Event: 2nd Annual Gene Therapy Analytical Development EU

Date: May 26, 2021

Abstract:

In-process analytics of vector capsid production is a critical optimization target in development of AAV-based gene therapy products. In this presentation we introduce a fast at-line HPLC based system that enables differentiation of vector capsid and empty capsid production in transfection mixtures. Case study results  demonstrating the effects of different process variables on capsid production and assembly are shown and insights about purification are also discussed.

Attachments

Full view

Presenter: Aleš Štrancar

Event: Genetic Vaccine Development for Infectious Diseases Summit

Date: May 20, 2021

Abstract:

  • Developments in gene therapy and threat of pandemics requests novel technologies to allow for efficient manufacturing of very large biomolecules and nanoparticles within short time.
  • Convective Interaction Media with open channel structures resulting in no shear forces allows for fast and very efficient manufacturing of mRNA, pDNA, Adeno and other VLP based Covid vaccines.
  • Ultra-sensitive DNA assay and fast in-process control using PATfix systems are introduced for production of safer Covid vaccines.

Attachments

Full view